[Proxodolol--a new beta- and alpha-adrenoblockader].

Abstract

The beta- and alpha-adrenoceptor blocking activity, the specificity of its beta-adrenoceptor blocking action, partial agonistic and membrane-stabilizing properties, as well as antihypertensive, antiarrhythmic, and anti-ischemic effects were studied. Proxodolol was shown to be superior to labetalol in its beta-adrenoceptor blocking action and similar to it in its alpha-adrenoceptor blocking agent. The drug has no a partial agonistic activity and produces a moderate membrane-stabilizing action. Proxodolol proved to be effective in treating experimental hypertension and arrhythmias. It exhibits anti-ischemic activity.

• Authors: S D Iuzhakov, O V Dolgun, E V Dorodnikova, E P Aniukhovskiĭ, G N Baldenkov, L V Rozenshtraukh, O S Medvedev, M D Mashkovskiĭ
• Journal: Eksperimental'naia i klinicheskaia farmakologiia (Eksp Klin Farmakol) 1994 May-Jun Vol. 57 Issue 3 Pg. 30-3 ISSN: 0869-2092 [Print] Russia (Federation)
• Vernacular Title: Proksodolol--novyĭ (beta-, al'fa-)adrenoblokator.
• PMID: 7914115 (Publication Type: Comparative Study, English Abstract, Journal Article)

Chemical References

• Adrenergic alpha-Antagonists
• Adrenergic beta-Antagonists
• Oxadiazoles
• proxodolol
• Oxprenolol
• Propranolol
• Labetalol

Topics

• Adrenergic alpha-Antagonists (pharmacology, therapeutic use)
• Adrenergic beta-Antagonists (pharmacology, therapeutic use)
• Animals
• Arrhythmias, Cardiac (drug therapy)
• Cats
• Cell Membrane (drug effects)
• Dogs
• Drug Evaluation, Preclinical
• Heart (drug effects)
• Heart Rate (drug effects)
• Hypertension (drug therapy)
• In Vitro Techniques
• Labetalol (pharmacology)
• Male
• Oxadiazoles (pharmacology, therapeutic use)
• Oxprenolol (pharmacology)
• Propranolol (pharmacology)
• Rabbits
• Rats